116 HR 4667 IH: Biomedical Innovation Expansion Act of 2019 U.S. House of Representatives 2019-10-11 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I116th CONGRESS1st SessionH. R. 4667IN THE HOUSE OF REPRESENTATIVESOctober 11, 2019Ms. Sherrill (for herself, Mr. Levin of California, and Ms. Spanberger) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo amend the 21st Century Cures Act to reauthorize funding for NIH innovation projects, and for other purposes.

1.

Short title

This Act may be cited as the Biomedical Innovation Expansion Act of 2019.

2.

Reauthorization of NIH innovation proj­ects

(a)

Transfers

Section 1001(b)(2)(A) of the 21st Century Cures Act (Public Law 114–255) is amended by striking clauses (v) through (x) and inserting the following: (v)For fiscal year 2021, $854,000,000. (vi)For fiscal year 2022, $1,051,000,000. (vii)For fiscal year 2023, $1,345,000,000. (viii)For fiscal year 2024, $1,271,000,000. (ix)For fiscal year 2025, $1,301,000,000. (x)For fiscal year 2026, $1,306,000,000. (xi)For fiscal year 2027, $1,336,000,000. (xii)For fiscal year 2028, $1,376,000,000. (xiii)For fiscal year 2029, $1,436,000,000. (xiv)For fiscal year 2030, $1,469,000,000.. (b)

Authorization of appropriations

Section 1001(b)(3)(A) of the 21st Century Cures Act (Public Law 114–255) is amended by striking 2026 and inserting 2030. (c)

Offsetting future appropriations

Section 1001(b)(3)(B) of the 21st Century Cures Act (Public Law 114–255) is amended by striking 2026 and inserting 2030. (d)

NIH innovation projects

Section 1001(b)(4) of the 21st Century Cures Act (Public Law 114–255) is amended— (1)in the matter preceding subparagraph (A), by striking 2026 and inserting 2030; (2)in subparagraph (A)— (A)in the matter preceding clause (i), by striking $1,455,000,000 and inserting $4,413,000,000; and (B)by striking clauses (v) through (x) and inserting the following: (v)For fiscal year 2021, $209,000,000. (vi)For fiscal year 2022, $300,000,000. (vii)For fiscal year 2023, $419,000,000. (viii)For each fiscal years 2024 through 2030, $430,000,000.; (3)in subparagraph (B)— (A)in the matter preceding clause (i), by striking $1,511,000,000 and inserting $4,428,000,000; and (B)by striking clauses (v) through (x) and inserting the following: (v)For fiscal year 2021, $250,000,000. (vi)For fiscal year 2022, $302,000,000. (vii)For fiscal year 2023, $450,000,000. (viii)For each of fiscal years 2024, 2025, and 2026, $400,000,000. (ix)For fiscal year 2027, $425,000,000. (x)For fiscal years 2028, $450,000,000. (xi)For each of fiscal years 2029 and 2030, $500,000,000.; (4)in subparagraph (C)— (A)in the matter preceding clause (i), by striking $1,800,000,000 and inserting $3,312,000,000; and (B)by amending clause (vii) to read as follows: (vii)For each of fiscal years 2023 through 2030, $216,000,000.; (5)in subparagraph (D)— (A)in the matter preceding clause (i), by striking $30,000,000 and inserting $250,000,000; and (B)by striking clause (iv) and inserting the following: (iv)For each of fiscal years 2021, 2022, and 2023, $50,000,000. (v)For each of fiscal years 2024 through 2030, $10,000,000.; and (6)by adding at the end the following: (E)To support research related to combating antimicrobial resistance and antibiotic resistant bacteria, not to exceed a total of $1,635,000,000, as follows: (i)For fiscal year 2021, $100,000,000. (ii)For each of fiscal years 2022 through 2024, $150,000,000. (iii)For each of fiscal years 2025 through 2027, $175,000,000. (iv)For each of fiscal years 2028 and 2029, $180,000,000. (v)For fiscal year 2030, $200,000,000. (F)To support research and research activities related to rare diseases or conditions, not to exceed a total of $758,000,000, as follows: (i)For fiscal year 2021, $50,000,000. (ii)For fiscal year 2022, $55,000,000. (iii)For fiscal year 2023, $60,000,000. (iv)For fiscal year 2024, $65,000,000. (v)For fiscal year 2025, $70,000,000. (vi)For fiscal year 2026, $75,000,000. (vii)For fiscal year 2027, $80,000,000. (viii)For fiscal year 2028, $90,000,000. (ix)For fiscal year 2029, $100,000,000. (x)For fiscal year 2030, $113,000,000.. (e)

Workplan

Section 1001(c)(1)(A) of the 21st Century Cures Act (Public Law 114–255) is amended by striking 2026 and inserting 2030. (f)

Recommendations

Section 1001(c)(1)(C)(i) of the 21st Century Cures Act (Public Law 114–255) is amended by striking 2026 and inserting 2030. (g)

Annual reports

Section 1001(c)(2)(A) of the 21st Century Cures Act (Public Law 114–255) is amended by striking 2027 and inserting 2030. (h)

Sunset

Section 1001(e) of the 21st Century Cures Act (Public Law 114–255) is amended by striking September 30, 2026 and inserting September 30, 2030.